No Data
Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner's Portfolio?
J.P. Morgan Remains a Buy on Lineage, Inc. (LINE)
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Lineage Explores Connection Between Food Infrastructure and Economic Development in New Research by Economist Impact
Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital
Lineage Cell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of up to a $66 Million Registered Direct Offering. Also, D Boral Capital Maintained a Buy Rating on the Stock and Lowered Its Price Target From $3 to $2.